Abstract PS7-03: A first-in-human phase 1a/b trial of LOXO-783, a potent, highly mutant-selective, brain-penetrant, allosteric PI3Kα H1047R inhibitor in PIK3CA H1047R-mutant advanced breast cancer and other solid tumors: Results from the PIKASSO-01 studyKomal Jhaveri, Funda Meric-Bernstam, Antonio Giordano et al.|Clinical Cancer Research|2025Cited by 2